Breaking News
July 19, 2018 - Deleting single gene in gut bacteria affects metabolism, reduces weight gain in mice
July 19, 2018 - Study finds major discrepancies in prescription drug labeling pregnancy information across four countries
July 19, 2018 - Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma
July 19, 2018 - Watching the immune system in action reveals what happens when things goes wrong
July 19, 2018 - Increasing blood sugar levels improves memory and performance in older adults
July 19, 2018 - Connection between self-regulation and obesity appears to be different for girls and boys
July 19, 2018 - Researchers develop new, less destructive method for whitening teeth
July 19, 2018 - Revving up innate control of viral infection requires a three-cell ignition
July 19, 2018 - Inaccurate direct-to-consumer raw genetic data can harm patients, new research suggests
July 19, 2018 - Weight loss surgery is effective under the right situations
July 19, 2018 - BioTek awarded patent for autofocus feature on microplate reader
July 19, 2018 - Low-carb diets reduce stiffness of arteries in women and promote weight loss in men
July 19, 2018 - New review examines cannabinoids’ potential for direct treatment of cancer
July 19, 2018 - Allergic responses may help protect the skin against cancer, research suggests
July 19, 2018 - Inappropriate Prescribing of Abx High in Urgent Care Centers
July 19, 2018 - Many at risk for HIV despite lifesaving pill
July 19, 2018 - Tips for doctors and parents on the harms of marijuana use for teens
July 18, 2018 - Researchers detect presence of IgE antibodies after kidney transplantation
July 18, 2018 - New technique allows researchers to create large scale, personalized bone grafts
July 18, 2018 - Smoking May Boost Atrial Fibrillation Risk
July 18, 2018 - Genome editing method targets AIDS virus
July 18, 2018 - These things matter: Medical complications are not inevitable, a physician writes
July 18, 2018 - Cognitive functions often wilt as water departs the body, shows study
July 18, 2018 - Origins of bread found 14,400 years ago in Jordan
July 18, 2018 - Low-dose ketamine found to be as effective as opioids for treating acute pain
July 18, 2018 - Novel bioengineering technique could help repair bone defects
July 18, 2018 - Researchers identify new potential target protein for colon cancer
July 18, 2018 - Air pollution contributes significantly to diabetes globally
July 18, 2018 - Cell membrane’s importance offers new strategy to fight infections
July 18, 2018 - Researchers identify key protein involved in irregular brain cell activity
July 18, 2018 - 3D modeling of drug resistance could lead to more effective cancer treatment
July 18, 2018 - Hunger hormones could be key to new treatments for drug, alcohol addiction
July 18, 2018 - Nitrate-cured meats may contribute to mania, study finds
July 18, 2018 - Why men may recover more quickly from influenza infections than women
July 18, 2018 - Study finds discharge against medical advice as predictor of readmissions in heart attack patients
July 18, 2018 - KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD
July 18, 2018 - Self-control and obesity: Gender matters in children
July 18, 2018 - Bioengineers, diabetes researchers convene to discuss future concepts for precision medicine
July 18, 2018 - New findings support more conservative use of ED neuroimaging for non-index seizures
July 18, 2018 - Practicing yoga benefits pregnant women, study suggests
July 18, 2018 - New strategy may lead to more accurate breast cancer diagnoses
July 18, 2018 - FDA Approves Symtuza (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
July 18, 2018 - New guide helps hospitals pick right partner to handle hospitalist services
July 18, 2018 - Deep data dive helps predict cerebral palsy
July 18, 2018 - Stricter firearm legislation associated with reduced murder and suicide rates
July 18, 2018 - Physical and sexual abuse in childhood associated with endometriosis risk
July 18, 2018 - Omega 3 supplements do not reduce risk of heart disease, stroke or death
July 18, 2018 - GSA’s new publication provides support for safe use of OTC analgesics by older adults
July 18, 2018 - Researchers receive grant from U.S. Department of Education to study children with HFASD
July 18, 2018 - Early childhood adversity increases sensitivity of the body’s immune response to cocaine
July 18, 2018 - Parental incarceration affects health behaviors of children in adulthood
July 18, 2018 - Researchers find that yellow fever and Asian tiger mosquitoes can carry new virus
July 18, 2018 - Two Regimens Fail to Stop Declines in β-Cell Function
July 18, 2018 - Researchers apply computing power to track the spread of cancer
July 18, 2018 - Olfactory receptors play pathophysiological role in all organs than merely smell perception
July 18, 2018 - Fish consumption associated with lower risk of early death
July 18, 2018 - MR Solutions’ 7T MRI imaging system installed at University of Hawaii
July 18, 2018 - Humorous ads screened around World Cup game achieve higher biometric response than sporty ads
July 18, 2018 - New study demonstrates little effect of hormone therapy on artery thickness
July 18, 2018 - A 3-Pronged Plan to Cut Type 2 Diabetes Risk
July 18, 2018 - New clues to sepsis may speed diagnosis
July 18, 2018 - Stars of Stanford Medicine: Improving cardiovascular health in Africa and beyond
July 18, 2018 - Heart attack risk continues to increase among pregnant women, study finds
July 18, 2018 - Few tips to help avoid sunburns in summer
July 18, 2018 - High-fat diet and systemic inflammation contribute to progression of prostate cancer
July 18, 2018 - Researchers develop 3D map of gene interactions that play key role in heart disease
July 18, 2018 - Conservative management of lung subsolid nodules reduces overtreatment and unnecessary surgery
July 18, 2018 - Report warns of dog illness that can spread to owners
July 18, 2018 - A winning essayist’s tips for keeping track of scientific facts
July 18, 2018 - Researchers seek to understand role of APOE mutation in Alzheimer’s disease
July 18, 2018 - Animal studies reveal brain changes responsible for appetite effects of cannabis
July 18, 2018 - New ZEISS ZEN Intellesis machine allows segmentation of correlative microscopy
July 18, 2018 - Study findings highlight importance of early detection of SMA through newborn screening
July 18, 2018 - Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of Pixuvri (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
July 18, 2018 - Diabetes researchers find switch for fatty liver disease
July 18, 2018 - The future of the microbiome: A conversation
July 18, 2018 - States attacking ACA would hurt most if shield on preexisting conditions were axed
July 18, 2018 - Novel delivery system for bacteriophages could offer new way to battle lung infections
July 18, 2018 - PTSD may increase risk of stroke, heart attack in World Trade Center response crews
July 18, 2018 - Finding the right protective eyewear for young athletes
FDA approves new drug Zelboraf for Erdheim-Chester disease

FDA approves new drug Zelboraf for Erdheim-Chester disease

image_pdfDownload PDFimage_print

The United States Food and Drugs Administration (FDA) has approved Zelboraf (vemurafenib), a drug for the treatment of adults with a are type of blood cancer called Erdheim-Chester Disease or ECD.

Zelboraf (vemurafenib) is already approved for the treatment of persons with a certain type of genetic mutation called the BRAF V600E leading to cancers such as skin cancers or melanomas. Now the approval has been extended to ECD. This is the first drug approved for this rare type of blood cancer.

Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research in his statement said, “Today’s approval of Zelboraf for patients with ECD demonstrates how we can apply knowledge of the underlying genetic characteristics of certain malignancies to other cancers…This product was first approved in 2011 to treat certain patients with melanoma that harbor the BRAF V600E mutation, and we are now bringing the therapy to patients with a rare cancer with no approved therapies.”

According to the FDA statement, ECD is a slowly progressing type of blood cancer. It starts in the bone marrow. There is an increased production of a certain type of cells called histiocytes. These are a type of white blood cells and excess numbers of these get accumulated in several organs of the body such as heart, lungs, brain etc. There are 600 to 700 individuals worldwide with this rare form of cancer. They do not live long and around one in two of these patients have the BRAF V600 genetic mutation. This new drug Zelboraf is a kinase inhibitor. This can stop the cell growth in certain types of cells by blocking certain key enzymes.

For approval, the manufacturers who have been now granted approval – Hoffman-LaRoche, Inc -submitted results from a clinical trial that showed its effectiveness and safety in these patients. They tested the drug on 22 patients with ECD who were positive for the BRAF-V600-mutation. They tested for partial or complete reduction in the tumor size and called it an overall response rate. Eleven patients of the 22 showed partial response to the drug in tumor reduction while 1 patients showed a complete response with complete tumor reduction. This proved the efficacy of the new drug.

The trial also looked at the safety of this medication and found that Zelboraf leads to joint pain, raised rash, tiredness, skin growths, loss of hair and change in the electrical activity of the heart. Sometimes Zelboraf may lead to development of secondary cancers such as those of skin or squamous cell carcinomas etc. It may also cause BRAF wild-type melanoma or skin cancer worsening and lead to allergic reactions such as anaphylaxis or Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) that could become fatal or life-threatening. The drug may rarely lead to heart rhythm abnormalities or arrhythmias and also severe liver damage. It may damage the eyes or may lead to kidney damage. Pregnant women should not be given this medication as it may severely harm the growing fetus.

Zelboraf received a priority review and got an orphan drug status. This means that the drug was approved for few numbers of patients who have a rare disease or condition. These incentives encourage new drug development in rare conditions.

Source:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm583931.htm

f2148f30-f0ab-4939-8196-5a9a6a328419|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Anaphylaxis, Blood, Blood Cancer, Bone, Bone Marrow, Brain, Cancer, Carcinomas, Cell, Clinical Trial, Drugs, Genetic, Hair, Heart, Hematology, Joint Pain, Kidney, Kinase, Kinase Inhibitor, Liver, Lungs, Melanoma, Mutation, Oncology, Pain, Rare Disease, Skin, Skin Cancer, Tumor

Tagged with:

About author

Related Articles